IDH1 mutations in diffusely infiltrating astrocytomas: Grade specificity, association with protein expression, and clinical relevance

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 177-184

  Thota, Balaram ^a   Shukla, Sudhanshu K ^a   Srividya, Mallavarapu R ^a   Shwetha, Shivayogi D ^a   Arivazhagan, Arimappamagan ^a   Thennarasu, Kandavel ^b   Chickabasaviah, Yasha T ^a   Hegde, Alangar S ^c   Chandramouli, Bangalore A ^a   Somasundaram, Kumarvel ^a   Santosh, Vani ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

Author keywords

Astrocytoma; DNA sequencing; IDH1; Immunohistochemistry; Prognosis; Somatic mutation; Survival

Indexed keywords

ARGININE; HISTIDINE; ISOCITRATE DEHYDROGENASE 1; MONOCLONAL ANTIBODY;

ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CODON; CONTROLLED STUDY; DIFFUSE ASTROCYTOMA; DIFFUSELY INFILTRATING ASTROCYTOMA; DISEASE DURATION; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTITUTION REACTION;

AMINO ACID SUBSTITUTION; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS;

EID: 84865407680     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPZOIY3WY4KIKE     Document Type: Article

References (37)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
2. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116::597-602.
3. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
4. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurol Oncol 2009;11:341-347.
5. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
7. Van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
8. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1 R132) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009;30:7-11.
9. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353-355.
10. Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP (+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999;274:30527-30533.
11. Margittai E, Bánhegyi G. Isocitrate dehydrogenase: a NADPH-generating enzyme in the lumen of the endoplasmic reticulum. Arch Biochem Biophys. 2008;471:184-190. (Pubitemid 351296195)
12. Narahara K, Kimura S, Kikkawa K, et al. Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet. 1985;71:37-40. (Pubitemid 16252285)
13. Koshland DE Jr., Walsh K, LaPorte DC. Sensitivity of metabolic fluxes to covalent control. Curr Top Cell Regul. 1985;27:13-22.
14. Shechter I, Dai P, Huo L, et al. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J Lipid Res. 2003;44:2169-2180. (Pubitemid 37509633)
15. Lee SM, Koh HJ, Park DC, et al. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32:1185-1196. (Pubitemid 34603355)
16. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599-601.
17. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:150-154.
18. Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 2004;279:33946-33957. (Pubitemid 39063045)
19. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
20. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119:487-494.
21. Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-123.
22. Ichimura K, Ohgaki H, Kleihues P, et al. Molecular pathogenesis of astrocytic tumours. J Neurooncol 2004;70:137-160. (Pubitemid 39549305)
23. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93-108. (Pubitemid 40287792)
24. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
25. Gravendeel LA, Kloosterhof NK, Bralten LB, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 2010;31:E1186-E1199.
26. Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100:1996-1998.
27. Jha P, Suri V, Sharma V, et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol. 2011;91:385-393.
28. Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119:501-507.
29. Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 2011;2:345-357.
30. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008;3:152-156. (Pubitemid 351264133)
31. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;19:6002-6007.
32. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707-718.
33. Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia. 2011;59:1200-1204.
34. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27:5743-5750.
35. Uno M, Oba-Shinjo SM, Silva R, et al. IDH1 mutations in a Brazilian series of glioblastoma. Clinics (São Paulo) 2011;66:163-165.
36. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radio chemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-5880.
37. Hofer S, Lassman AB. Molecular markers in gliomas: impact for the clinician. Target Oncol 2010;5:201-210.